Tempus AI expands multi-year collaboration giving Gilead enterprise-wide access to Lens platform and multimodal real-world oncology data

The enrichment is done by Tempus: the Lens platform bundles Tempus' multimodal RWD, AI computing, foundation models and Tempus One 'co-scientist' agent, and the expanded deal explicitly adds 'dedicated Tempus analytical services' on top of enterprise-wide access. Gilead is the consumer, not the enricher.

Tempus keeps the rake and it is owned: the substrate (8.5M+ patient records), the tooling, and the human analysts all sit inside Tempus' perimeter. Financial terms are not disclosed so the split is not visible, but the workflow is Tempus-fronted end to end.

For Gilead specifically, the substrate is worth something because Gilead is pushing an oncology franchise (Trodelvy in 1L mTNBC, two cancer launches slated for 2026) that needs biomarker-defined cohorts and trial-design evidence Gilead cannot synthesise from its own trial data at that scale.

Access to the Lens environment and de-identified multimodal data crossed to Gilead; the underlying patient records themselves did not leave Tempus' perimeter — Gilead works inside the platform, consistent with the prior arrangement letting the drugmaker 'use' the de-identified data rather than take it.

Not determinable — no financial terms are public, and Lens is already used by 19 of the top 20 biopharma, which suggests Tempus has pricing leverage, but whether this specific enterprise expansion captures that leverage cannot be read from the release.